Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SOUTH SAN FRANCISCO, Calif., March 01, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences.
- Sean McCarthy, D. Phil., president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference on March 13, 2018, at 10:00 a.m. ET.
- Debanjan Ray, Chief Financial Officer and Head of Corporate Development, will present at the Barclay’s Global Health Conference on March 15, 2018, at 8:30 a.m. ET.
A live audio webcast for each event will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Media:
Spectrum
Christine Quern
[email protected]
202-587-2588
Investors:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
